-
1
المؤلفون: Giebel, Sebastian, Labopin, Myriam, Sobczyk-Kruszelnicka, Malgorzata, Stelljes, Matthias, Byrne, Jenny, Fegueux, Nathalie, Beelen, Dietrich, Rovira, Montserrat, Spyridonidis, Alexandros, Blaise, Didier, Bornhäuser, Martin, Karadogan, Ihsan, Savani, Bipin, Nagler, Arnon, Mohty, Mohamad, Martin, Sonja, Chevallier, Patrice, Neubauer, Andreas, Damaj, Gandhi, Koc, Yener, Ganser, Arnold, Collin, Matthew, Yakoub-Agha, Ibrahim, Ozdogu, Hakan, Araujo, Mercedes Colorado, Itäla-Remes, Maija, Orchard, Kim, Isaksson, Cecilia, Bethge, Wolfgang, Martin, Hans, Aljurf, Mahmoud, Faber, Edgar, Caballero, Dolores, Zák, Pavel, Leleu, Xavier, Bay, Jacques-Olivier, Rohrlich, Pierre-Simon, Kröger, Nicolaus, Huynh, Anne, Schäfer-Eckart, Kerstin, Milpied, Noel, Lenhoff, Stig, Ho, Aloysius, López, Jose Luis Bello, Mordini, Nicola, Lioure, Bruno, Halaburda, Kazimierz, Olivieri, Attilio, Gedde-Dahl, Tobias, Protheroe, Rachel, Tischer, Johanna, Klammer, Matthias, Clausen, Johannes, Potter, Victoria, Ladetto, Marco, Tilly, Herve, Deconinck, Eric, Brecht, Arne, Müller, Lutz Peter, Heinicke, Thomas, Carrete, Juan Pio Torres, Bazarbachi, Ali, Reményi, Péter, Rubio, Marie Thérèse, Fanin, Renato, Pérez-Simón, Jose Antonio, Niels, Murawski, Diez-Martin, J., Arat, Mutlu, Hermine, Olivier, Socié, Gerard, Cornelissen, Jan, Santarone, Stella, Guyotat, Denis, Bulabois, Claude Eric, Bernasconi, Paolo, Johansson, Jan-Erik, Vrhovac, Radovan, Greinix, Hildegard, Lorenzo, José Luis López, Apte, Shashikant, Craddock, Charles, Kobbe, Guido, Zahrani, Mohsen Al, Dreger, Peter, Lange, Andrzej, Tbakhi, Abdelghani, Meijer, Ellen, Llamas, Carlos Vallejo, Santasusana, Josep Maria Ribera, Corradini, Paolo, Benedetti, Fabio, Rambaldi, Alessandro, Gandemer, Virginie, Malfuson, Jean-Valère, Kaare, Ain, Risitano, Antonio, Petrini, Mario, Selleri, Carmine, Wu, Depei
المساهمون: Hematology, CCA - Cancer Treatment and quality of life, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
المصدر: Bone Marrow Transplantation, 56(2), 481-491. Nature Publishing Group
Giebel, S, Labopin, M, Sobczyk-Kruszelnicka, M, Stelljes, M, Byrne, J L, Fegueux, N, Beelen, D W, Rovira, M, Spyridonidis, A, Blaise, D, Bornhäuser, M, Karadogan, I, Savani, B N, Nagler, A, Mohty, M & Principal investigators of the contributing institutions 2021, ' Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT ', Bone Marrow Transplantation, vol. 56, no. 2, pp. 481-491 . https://doi.org/10.1038/s41409-020-01050-7Test
Bone Marrow Transplantation
Bone Marrow Transplantation, 2021, 56 (2), pp.481-491. ⟨10.1038/s41409-020-01050-7⟩مصطلحات موضوعية: medicine.medical_specialty, Transplantation Conditioning, MESH: Busulfan, Medizin, MESH: Graft vs Host Disease, Graft vs Host Disease, [SDV.CAN]Life Sciences [q-bio]/Cancer, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Busulfan, MESH: Hematopoietic Stem Cell Transplantation, MESH: Transplantation Conditioning, Retrospective Studies, Transplantation, Acute leukemia, MESH: Humans, MESH: Middle Aged, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, MESH: Retrospective Studies, Retrospective cohort study, Hematology, Middle Aged, Total body irradiation, Fludarabine, Leukemia, Myeloid, Acute, Regimen, 030220 oncology & carcinogenesis, MESH: Vidarabine, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH: Leukemia, Myeloid, Acute, business, MESH: Whole-Body Irradiation, Vidarabine, Whole-Body Irradiation, 030215 immunology, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a271bda3480115a5c698ba5b59f0ad1Test
https://doi.org/10.1038/s41409-020-01050-7Test -
2
المؤلفون: Zina Chir, Noel Milpied, Mauricette Michallet, Marc Renaud, Jean-Michel Boiron, Bernard Rio, Ibrahim Yakoub-Agha, Eric Deconinck, Quoc-Hung Le, Didier Blaise, Franck E. Nicolini, Bruno Lioure, Michel Attal, Helene Esperou, Thomas Prebet, Jean-Henri Bourhis, Mohamad Mohty, Pierre Bordigoni
المساهمون: Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'hématologie clinique, Hôpital Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Agence de la biomédecine [Saint-Denis la Plaine], Laboratoire d'Hématologie [Purpan], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Service des maladies du sang, CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux]-Groupe Hospitalier Sud, Service d'onco-hématologie, CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Département d'Hématologie et Oncologie Médicale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service greffe de moelle osseuse, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Hôpital Haut-Lévêque, Université Sciences et Technologies - Bordeaux 1-CHU Bordeaux [Bordeaux], Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Sciences et Technologies - Bordeaux 1 (UB)-CHU Bordeaux [Bordeaux], Saas, Philippe
المصدر: Experimental Hematology
Experimental Hematology, Elsevier, 2008, 36 (5), pp.535-44. ⟨10.1016/j.exphem.2008.01.017⟩
Experimental Hematology, 2008, 36 (5), pp.535-44. ⟨10.1016/j.exphem.2008.01.017⟩مصطلحات موضوعية: Oncology, Male, MESH: Remission Induction, Cancer Research, Multivariate analysis, Transplantation Conditioning, MESH: Registries, MESH: Busulfan, medicine.medical_treatment, Graft vs Host Disease, Hematopoietic stem cell transplantation, 0302 clinical medicine, MESH: Antilymphocyte Serum, MESH: Risk Factors, Risk Factors, MESH: Child, Medicine, Registries, Child, MESH: Transplantation Conditioning, MESH: Treatment Outcome, MESH: Aged, MESH: Middle Aged, MESH: Time, Remission Induction, Hematopoietic Stem Cell Transplantation, MESH: Follow-Up Studies, Hematology, Total body irradiation, Middle Aged, MESH: Infant, MESH: Predictive Value of Tests, 3. Good health, Fludarabine, Treatment Outcome, MESH: Survival Analysis, 030220 oncology & carcinogenesis, Reduced Intensity Conditioning, Child, Preschool, Hematologic Neoplasms, MESH: Vidarabine, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, France, Vidarabine, medicine.drug, Adult, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, Adolescent, MESH: Graft vs Host Disease, MESH: Multivariate Analysis, Disease-Free Survival, Time, 03 medical and health sciences, Predictive Value of Tests, Internal medicine, MESH: Transplantation, Homologous, Genetics, Humans, Transplantation, Homologous, Molecular Biology, Busulfan, MESH: Hematopoietic Stem Cell Transplantation, Aged, Antilymphocyte Serum, Retrospective Studies, MESH: Adolescent, MESH: Humans, business.industry, MESH: Child, Preschool, Infant, MESH: Adult, MESH: Retrospective Studies, Retrospective cohort study, Cell Biology, Survival Analysis, MESH: Male, Surgery, MESH: France, Transplantation, MESH: Disease-Free Survival, Multivariate Analysis, business, MESH: Female, MESH: Hematologic Neoplasms, 030215 immunology, Follow-Up Studies
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::007eddc9d70852611e759c0dd479d80eTest
https://pubmed.ncbi.nlm.nih.gov/18346838Test -
3
المؤلفون: Patrice Chevalier, Reza Tabrizi, Hervé Tilly, Bruno Lioure, Eric Deconinck, Gérard Socié, Jill-Patrice Cassuto, Lionel Ades, Didier Blaise, Mauricette Michallet, Mathieu Kuentz, Michel Attal, Pierre Bordigoni, Thierry Facon, Frédéric Garban, Jean-Paul Vernant, Stéphane Vigouroux, Noel Milpied, Marc Bernard, Norbert Ifrah, Jean-Henri Bourhis, Marc Renaud, Raphaël Porcher
المساهمون: Centre Hospitalier Universitaire [Rennes], Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire d'Hématologie [Purpan], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Hôpital Haut-Lévêque, Université Sciences et Technologies - Bordeaux 1-CHU Bordeaux [Bordeaux], Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon, Laboratoire d'Immunologie, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet, Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Claude Huriez [Lille], CHU Lille, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital de la Milétrie, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service d'Hématologie, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service d'onco-hématologie, CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Saas, Philippe, Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Sciences et Technologies - Bordeaux 1 (UB)-CHU Bordeaux [Bordeaux], Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC)
المصدر: Haematologica
Haematologica, Ferrata Storti Foundation, 2007, 92 (5), pp.627-34
Haematologica, 2007, 92 (5), pp.627-34
HALمصطلحات موضوعية: Male, Oncology, MESH: Remission Induction, Transplantation Conditioning, MESH: Busulfan, medicine.medical_treatment, Graft vs Host Disease, MESH: Antibodies, Monoclonal, 0302 clinical medicine, MESH: Antilymphocyte Serum, Antineoplastic Combined Chemotherapy Protocols, Melphalan, Etoposide, MESH: Etoposide, MESH: Transplantation Conditioning, MESH: Treatment Outcome, Hematology, MESH: Middle Aged, Remission Induction, Hematopoietic Stem Cell Transplantation, Antibodies, Monoclonal, Total body irradiation, 3. Good health, Survival Rate, MESH: Antineoplastic Combined Chemotherapy Protocols, 030220 oncology & carcinogenesis, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, Graft vs Leukemia Effect, RIC allogeneic transplantation, Disease-Free Survival, 03 medical and health sciences, MESH: Melphalan, Humans, Cyclophosphamide, Aged, Antilymphocyte Serum, Retrospective Studies, MESH: Humans, MESH: Cyclophosphamide, MESH: Adult, MESH: Retrospective Studies, Survival Analysis, Regimen, MESH: Disease-Free Survival, MESH: Female, Busulfan, MESH: Combined Modality Therapy, T-Lymphocytes, MESH: Carmustine, Kaplan-Meier Estimate, MESH: Proportional Hazards Models, MESH: Lymphoma, Non-Hodgkin, hemic and lymphatic diseases, MESH: Cytarabine, MESH: Data Collection, MESH: Kaplan-Meiers Estimate, MESH: Aged, Data Collection, Lymphoma, Non-Hodgkin, Cytarabine, Middle Aged, Combined Modality Therapy, Fludarabine, MESH: Salvage Therapy, Treatment Outcome, medicine.anatomical_structure, MESH: Survival Analysis, MESH: Vidarabine, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, France, MESH: Whole-Body Irradiation, Vidarabine, Whole-Body Irradiation, medicine.drug, Adult, MESH: Survival Rate, MESH: Graft vs Host Disease, Internal medicine, medicine, MESH: Transplantation, Homologous, Transplantation, Homologous, MESH: Hematopoietic Stem Cell Transplantation, Proportional Hazards Models, Salvage Therapy, Chemotherapy, business.industry, MESH: Graft vs Leukemia Effect, Carmustine, low-grade lymphoma, MESH: Male, Surgery, Transplantation, MESH: France, MESH: T-Lymphocytes, Bone marrow, business, 030215 immunology
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f71a790778690350e9b7db0e36e46f8Test
https://www.hal.inserm.fr/inserm-00507510/file/627.pdfTest